Concomitant Radiation and Chemotherapy in Muscle-Invasive Bladder Cancer

  • Jürgen Dunst
  • Claus Rödel
  • Anthony Zietman
Part of the Medical Radiology book series (MEDRAD)


Bladder Cancer Clin Oncol Radiat Oncol Biol Phys Radical Cystectomy Radiation Therapy Oncology Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Advanced Bladder Cancer (ABC) (2005a) Meta-analysis collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data. Eur Urol 48:189–201CrossRefGoogle Scholar
  2. Advanced Bladder Cancer (ABC) (2005b) Meta-analysis collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur Urol 48:202–206CrossRefGoogle Scholar
  3. Arias F, Dominguez MA, Martinez E et al. (2000) Chemoradiotherapy for muscle invading bladder carcinoma. Final report of a single institutional organ-sparing program. Int J Radiat Oncol Biol Phys 47:373–378PubMedCrossRefGoogle Scholar
  4. Bassi P, Ferrante GD, Piazza N et al. (1999) Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. J Urol 161:1494–1497PubMedCrossRefGoogle Scholar
  5. Bellmunt J, Hussain M, Dinney CP (2003) Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol 46(Suppl): S85–S104PubMedGoogle Scholar
  6. Bredael JJ, Croker BP, Glenn JF (1980) The curability if invasive bladder cancer treated by radical cystectomy. Eur Urol 6:206–210PubMedGoogle Scholar
  7. Caffo O, Fellin G, Graffer U et al. (2003) Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer. Int J Radiat Oncol Biol Phys 57:1310–1316PubMedCrossRefGoogle Scholar
  8. Cervak J, Cufer T, Marolt F et al. (1991) Combined chemotherapy and radiotherapy in muscle-invasive bladder carcinoma. Complete remission results. ECCO Proc 6:abstract 561Google Scholar
  9. Chakravati A, Winter K, Wu CL et al. (2005) Expression of the epidermal growth factor receptor and Her-2 are predictors of favourable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatinbased chemotherapy: a report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 62:309–317CrossRefGoogle Scholar
  10. Chen WC, Liaw CC, Chuang CK et al. (2003) Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer. Int J Radiat Oncol Biol Phys 56:726–733PubMedCrossRefGoogle Scholar
  11. Cohen-Jonathan E, Muschel RJ, Gillies McKenna W et al. (2000) Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS. Radiat Res 154:125–132PubMedCrossRefGoogle Scholar
  12. Coppin CM, Gospodarowicz MK, James K et al. (1996) Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 14:2901–2907PubMedGoogle Scholar
  13. Danesi DT, Arcangeli G, Cruciani E et al. (2004) Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long-term results. Cancer 101:2540–2548PubMedCrossRefGoogle Scholar
  14. Dreicer R, Gustin DM, See WA, Williams RD (1996) Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy. J Urol 156:1606–1608PubMedCrossRefGoogle Scholar
  15. Dunst J, Sauer R, Schrott KM et al. (1994) Organ-sparing treatment of advanced bladder cancer: a 10-year experience. Int J Radiat Oncol Biol Phys 30:261–266PubMedGoogle Scholar
  16. Dunst J, Rödel C, Zietman A et al. (2001) Bladder preservation in muscle-invasive bladder cancer by conservative surgery and radiochemotherapy. Semin Surg Oncol 20:24–32PubMedCrossRefGoogle Scholar
  17. Dunst J, Rödel C (2003) Harnblase. In: Radioonkologie 2: Klinik. Hrsg: Bamberg M, Molls M, Sack H. Zuckschwerdt Verlag München. 672–691Google Scholar
  18. Eapen L, Stewart D, Danjoux C et al. (1989) Intraarterial cisplatin and concurrent radiation for locally advanced bladder cancer. J Clin Oncol 7:230–235PubMedGoogle Scholar
  19. Eapen L, Stewart D, Collins J, Peterson R (2004) Effective bladder sparing therapy with intra-arterial cisplatin and radiotherapy for localized bladder cancer. J Urol 172:1276–1280PubMedCrossRefGoogle Scholar
  20. Fellin G, Graffer U, Bolner A et al. (1997) Combined chemotherapy and radiation with selective organ preservation for muscle-invasive bladder carcinoma. A single-institution phase II study. Br J Urol 80:44–49PubMedGoogle Scholar
  21. Fossa SD, Waehre H, Aass N et al. (1993) Bladder cancer definitive radiation therapy of muscle invasive bladder cancer. A retrospective analysis of 317 patients. Cancer 72:3036–3043PubMedCrossRefGoogle Scholar
  22. Frazier HA, Robertson JE, Dodge RK, Paulson DF (1993) The value of pathologic factors in predicting cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer 71:3993–4001PubMedCrossRefGoogle Scholar
  23. Ghersi D, Stewart LA, Parmar MKB et al. (1995) Does neoadjuvant cisplatin-based chemotherapy improve the survival of patients with locally advanced bladder cancer: a metaanalysis of individual patient data from randomized clinical trials. Br J Urol:75–106Google Scholar
  24. Giuliani L, Giberti C, Martorana G et al. (1985) Results of radical cystectomy for primary bladder cancer. Retrospective study of more than 200 cases. Urology 26:243–248PubMedCrossRefGoogle Scholar
  25. Given RW, Parsons JT, McCarley D et al. (1995) Bladder-sparing multimodality treatment of muscle-invasive bladder cancer: a five-year follow-up. Urology 46:499–504PubMedCrossRefGoogle Scholar
  26. Gospodarowicz M (2002) Radiotherapy and organ preservation in bladder cancer: Are we ignoring the evidence? J Clin Oncol 20:3048–3050PubMedGoogle Scholar
  27. Gschwend JE, Fair WR, Vieweg J (2000) Radical cystectomy for invasive bladder cancer: contemporary results and remaining controversies. Eur Urol 38:121–130PubMedCrossRefGoogle Scholar
  28. Gupta AK, Cerniglia GJ, Ahmed MS et al. (2003) Radiation sensitisation of human cancer cells by inhibiting the acticity of PI3K using LY294002. Int J Radiat Oncol Biol Phys 56:846–853PubMedCrossRefGoogle Scholar
  29. Hagan MP, Winter KA, Kaufman DS et al. (2003) RTOG 97-06: initial report of a phase I–II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 57:665–672PubMedCrossRefGoogle Scholar
  30. Hautmann RE (1998) Complications and results after cystectomy in male and female patients with locally invasive bladder cancer. Eur Urol 33(Suppl 4):23–24PubMedCrossRefGoogle Scholar
  31. Herr HW (1987) Conservative management of muscle-infiltrating bladder cancer: prospective experience. J Urol 138:1162–1163PubMedGoogle Scholar
  32. Housset M, Maulard C, Chretien YC et al. (1993) Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol 11:2150–2157PubMedGoogle Scholar
  33. Housset M, Dufour E, Maulard-Durtux C et al. (1997) Concomitant 5-fluouracil-cisplatin and bifractionated split course radiation therapy for invasive bladder cancer. Proc Am Soc Clin Oncol 16:319, abstract 1139Google Scholar
  34. Hussain SA, Stocken DD, Peake DR et al. (2004) Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. Br J Cancer 90:2106–2111PubMedGoogle Scholar
  35. Kachnic LA, Kaufmann DS, Griffin PP et al. (1997) Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol 15:1022–1029PubMedGoogle Scholar
  36. Kaufman DS, Winter KA, Shipley WU (2000) The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist 5:471–476PubMedCrossRefGoogle Scholar
  37. Kent E, Sandler H, Montie J et al. (2004) Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial. J Clin Oncol 22:2540–2545PubMedCrossRefGoogle Scholar
  38. Kragelj B, Zaletel-Kragelj L, Sedmark B, Cufer T, Cervek J (2005) Phase II study of radiochemotherapy with vinblastine in invasive bladder cancer. Radiother Oncol 75:44–47PubMedCrossRefGoogle Scholar
  39. Maciejewski B, Majewski S (1991) Dose fractionation and tumour repopulation in radiotherapy for bladder cancer. Radiother Oncol 21:163–170PubMedCrossRefGoogle Scholar
  40. Maddineni SB, Sangar VK, Hendry JH et al. (2005) Differential radiosensitization by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines. Br J Cancer 92:125–130PubMedCrossRefGoogle Scholar
  41. Malkowicz SB, Nichols P, Lieskovsky G et al. (1990) The role of radical cystectomy in the management of high grade superficial bladder cancer (PA, P1, PIS and P2). J Urol 144:641–645PubMedGoogle Scholar
  42. Moore MJ, O’Sullivan B, Tannock I (1988) How expert physicians would wish to be treated if they had genitourinary cancer. J Clin Oncol 6:1736–1745PubMedGoogle Scholar
  43. Nichols RC, Sweetser MG, Mahmood SK et al. (2000) Radiation therapy and concomitant paclitaxel/carboplatin for muscle-invasive transitional cell carcinoma of the bladder: a well-tolerated combination. Int J Cancer 90:281–286PubMedCrossRefGoogle Scholar
  44. Nieuwenhuijzen JA, Horenblas S, Meinhardt W et al. (2004) Salvage cystectomy after failure of interstitial radiotherapy and external beam radiotherapy for bladder cancer. BMJ Int 94:793–797Google Scholar
  45. Pagano F, Bassi P, Galetti TP et al. (1991) Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J Urol 145:45–50PubMedGoogle Scholar
  46. Patel B, Forman J, Fontana J et al. (2005) A single institution experience with concurrent capecitabine and radiation therapy in weak and/or elderly patients with urothelial cancer. Int J Radiat Oncol Biol Phys 62:1332–1338PubMedCrossRefGoogle Scholar
  47. Peyromaure M, Slama J, Beuzeboc P et al. (2004) Concurrent chemoradiotherapy for clinical stage T2 bladder cancer: report of a single institution. Urology 63:73–77PubMedCrossRefGoogle Scholar
  48. Rödel C (2004) Current status of radiation therapy and combined-modality treatment for bladder cancer. Strahlenther Onkol 180:701–709PubMedCrossRefGoogle Scholar
  49. Rödel C, Grabenbauer GG, Kuehn R et al. (2002a) Organ preservation in patients with invasive bladder cancer: initial results of an intensified protocol of transurethral surgery and radiation therapy plus concurrent cisplatin and 5-fluorouracil. Int J Radiat Oncol Biol Phys 52:1303–1309PubMedCrossRefGoogle Scholar
  50. Rödel C, Grabenbauer GG, Kuehn R et al. (2002b) Combined modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 20:3061–3071PubMedCrossRefGoogle Scholar
  51. Rotman M, Aziz H, Porrazzo M et al. (1990) Treatment of advanced transitional cell carcinoma of the bladder with irradiation and concomitant 5-fluorouracil infusion. Int J Radiat Oncol Biol Phys 18:1131–1137PubMedGoogle Scholar
  52. Russell KJ, Boileau MA, Higano C et al. (1990) Combined 5-fluorouracil and irradiation for transitional cell carcinoma of the urinary bladder. Int J Radiat Oncol Biol Phys 19:693–699PubMedGoogle Scholar
  53. Sangar VK, McBain CA, Lyons J et al. (2005) Phase I study of conformal radiotherapy with concurrent gemncitabine in locally advanced bladder cancer. Int J Radiat Oncol Biol Phys 61:420–425PubMedCrossRefGoogle Scholar
  54. Sauer R, Birkenhake S, Kuehn R et al. (1998) Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer. Int J Radiat Oncol Biol Phys 40:121–127PubMedCrossRefGoogle Scholar
  55. Shelley MD, Wilt TJ, Barber J, Mason MD (2004) A meta-analysis of randomised trials suggest a survival benefit for combined radiotherapy and radical cystectomy compared with radical radiotherapy for invasive bladder cancer: Are these data relevant to modern practice? Clin Oncol 16:166–171CrossRefGoogle Scholar
  56. Shipley WU, Prot GR, Kaufman SD, Perrone TL (1987) Invasive bladder carcinoma. The importance of intial transurethral surgery and other significant prognostic factors for improved survival with full-dose irradiation. Cancer 60(Suppl) 3:514–520PubMedCrossRefGoogle Scholar
  57. Shipley WU, Winter KA, Kaufman DS (1998) Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 16:3576–3583PubMedGoogle Scholar
  58. Shipley WU, Zietman AL, Kaufman DS et al. (2005) Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates: the Massachusetts General Hospital and Radiation Therapy Oncology Group experiences. Semin Radiat Oncol 15:36–41PubMedCrossRefGoogle Scholar
  59. Skinner DG, Lieskovsky G (1988) 16 years experience in the management of patients with deeply invasive bladder cancer. Eur Urol 14(Suppl 1):30–31PubMedGoogle Scholar
  60. Skinner DG (1982) Management of invasive bladder cancer: a meticulous pelvic node dissection can make a difference. J Urol 128:34–36PubMedGoogle Scholar
  61. Smith JA Jr, Whitmore WF Jr (1981) Salvage cystectomy for bladder cancer after failure of definitive irradiation. J Urol 125:643–645PubMedGoogle Scholar
  62. Stein JP, Lieskovsky G, Cote R et al. (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 19:666–675PubMedGoogle Scholar
  63. Swanson DA, Eschenbach AC von, Bracken RB, Johnson DE (1981) Salvage cystectomy for bladder carcinoma. Cancer 47:2275–2279PubMedCrossRefGoogle Scholar
  64. Tester W, Porter A, Asbell S et al. (1993) Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys 25:783–790PubMedGoogle Scholar
  65. Tester W, Porter A, Heaney J et al. (1996) Neoadjuvant combined modality therapy with possible organ preservation for invasive bladder cancer. J Clin Oncol 14:119–126PubMedGoogle Scholar
  66. Timmer PR, Hartlief HA, Hooijkaas JA (1985) Bladder cancer: pattern of recurrence in 142 patients. Int J Radiat Oncol Biol Phys 11:899–905PubMedGoogle Scholar
  67. Vaughn DJ, Manola J, Dreicer R et al. (2002) Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group. Cancer 95:1022–1027PubMedCrossRefGoogle Scholar
  68. Vaveris H, Delakas D, Anezinis P et al. (1997) Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control. Anticancer Res 17:4771–4780Google Scholar
  69. Vieweg J, Gschwend JE, Herr HW, Fair WR (1999) The impact of primary stage on survival in patients with lymph node positive bladder cancer. J Urol 161:72–76PubMedCrossRefGoogle Scholar
  70. Waehre H, Ous S, Klevmark B et al. (1993) A bladder cancer multi-institutional experience with total cystectomy for muscle invasive bladder cancer. Cancer 72:3044–3051PubMedCrossRefGoogle Scholar
  71. Wallace DM, Bloom HJ (1976) The management of deeply infiltrating (T3) bladder carcinoma: controlled trial of radical radiotherapy versus preoperative radiotherapy and radical cystectomy. Br J Urol 48:587–594PubMedCrossRefGoogle Scholar
  72. Weiss C, Roedel F, Wolf I et al. (2005) Combined-modality treatment and organ-preservation in bladder cancer. Do molecular markers predict outcome? Strahlenther Onkol 181:213–222PubMedCrossRefGoogle Scholar
  73. Wishnow KI, Tenney DM (1991) Will Rogers and the results of radical cystectomy for invasive bladder cancer. Urol Clin North Am 18:529–537PubMedGoogle Scholar
  74. Yu WS, Sagerman RH, Chung CT et al. (1985) Bladder carcinoma: experience with radical and preoperative radiotherapy in 421 patients. Cancer 56:1293–1299PubMedCrossRefGoogle Scholar
  75. Zapatero A, Martin de Vidales C, Marin A et al. (2000) Invasive bladder cancer: a single-institution experience with bladder-sparing approach. Int J Cancer 90:287–294PubMedCrossRefGoogle Scholar
  76. Zietman A, Skinner E (2005) Quality of life after radical treatment for invasive bladder cancer. Semin Radiat Oncol 15:55–59PubMedCrossRefGoogle Scholar
  77. Zietman AL, Shipley WU, Kaufman DS (1993) The combination of cis-platinum based chemotherapy and radiation in the treatment of muscle-invading transitional cell cancer of the bladder. Int J Radiat Oncol Biol Phys 27:161–170PubMedGoogle Scholar
  78. Zietman AL, Kaufman DS, Shipley WU et al. (1997) Phase I/II trial of transurethral surgery plus cisplatin and radiation therapy followed either by selective bladder preservation or radical cystectomy for patients with muscle-invading bladder cancer but without hydronephrosis. Int J Radiat Oncol Biol Phys (Suppl 2):abstract 42Google Scholar
  79. Zincke H, Patterson DE, Utz DC, Benson RC Jr (1985) Pelvic lymphadenectomy and radical cystectomy for transitional cell carcinoma of the bladder with pelvic nodal disease. Br J Urol 57:156–159PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2006

Authors and Affiliations

  • Jürgen Dunst
    • 1
  • Claus Rödel
    • 2
  • Anthony Zietman
    • 3
  1. 1.Department of Radiation OncologyUniversity Hospital Schleswig-Holstein, Campus LübeckLübeckGermany
  2. 2.Department of Radiation OncologyFriedrich-Alexander-Universität ErlangenErlangenGermany
  3. 3.Department of Radiation OncologyMassachusetts General HospitalBostonUSA

Personalised recommendations